Eisai Co. Ltd.

History

YearDetail
1941 Nihon Eisai Co. Ltd. is established in Saitama, eastern Japan.
1944 Sakuragaoka Laboratory Co. Ltd. and Nihon Eisai Co. Ltd. merge under the name Nihon Eisai Co. Ltd.
1950 Launched cardiotonic Neophyllin in Japan.
1952 Nihon Eisai Co. Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets in Japan.
1955 The company changes its name from Nihon Eisai Co. Ltd. to Eisai Co. Ltd.
1961 Eisai opens its Taipei Office. 
1969 Youda Co. Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.
1970 PT Eisai Indonesia is established.
1971 Toyoji opens the Naito Museum of Pharmaceutical Science and Industry.
1974 Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively.
1977 Launched Naturally derived vitamin E product Juvelux.
1981 Eisai U.S.A. Inc. is established.
1982 The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.
1989 Eisai Machinery GmbH is established in Germany.
1995 Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the U.S.
1998 Aricept is launched in France.
2004 Eisai Europe Ltd. is established.
2008 Eisai acquires MGI Pharma Inc.
2018 Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co. Inc. and Kenilworth.
2020 Unlimit Health Limited is established in Shanghai, China.
2022 Eisai Pharmaceuticals Africa (Pty) Ltd is established.
2023 LEQEMBI is launched in Japan.